BACKGROUND: The role of leptin in reproductive processes has received increasing attention. Because leptin has intrinsic angiogenic properties, may be induced by in¯ammatory cytokines and induces matrix metalloproteinases, we examined peritoneal¯uid (PF) leptin concentrations in women with endometriosis. METHODS: PF samples were collected from 60 women undergoing laparoscopy for endometriosis, and 18 controls undergoing tubal sterilization. Fifty of the women with endometriosis had received no prior hormonal treatment, while 10 with moderate± severe endometriosis were using GnRH agonists. RESULTS: Women with untreated endometriosis had signi®cantly higher (mean T T SD) PF leptin levels (34.9 T T 7.9 ng/ml) than controls (17.9 T T 4.1 ng/ml; P < 0.001). However, PF leptin levels were inversely correlated with the stage of disease (r = ±0.62; P < 0.001). Nevertheless, women with stage III±IV endometriosis maintained signi®cantly higher PF leptin levels (26.3 T T 4.8 ng/ml; P < 0.001) than controls. Although PF leptin levels were signi®cantly higher in the secretory versus proliferative phase of the menstrual cycle, they remained higher in both phases in women with untreated endometriosis. PF leptin levels in women on GnRH agonists were similar to controls. CONCLUSIONS: PF leptin levels are elevated in women with endometriosis, but inversely correlated with extent of disease. These ®ndings suggest a potential role for leptin in the pathogenesis of peritoneal endometriosis.
Introduction
Endometriosis is de®ned as the presence of endometrial tissue outside of the uterus. Although the pathogenesis of endometriosis is unknown, the theory of retrograde menstruation with attachment of endometrial fragments in conjunction with immunological and peritoneal factors that stimulate angiogenesis and cell growth is currently the most widely accepted explanation (Senturk and Arici, 1999; Starzinski-Powitz et al., 2001; Gazvani and Templeton, 2002; Witz, 2002) .
Growth factors and in¯ammatory mediators produced by peritoneal leukocytes are postulated to participate in the pathogenesis of endometriosis (Harada et al., 2001) . These include interleukins (IL), tumour necrosis factor (TNF)-a, regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein (MCP)-1, transforming growth factor (TGF)-b and vascular endothelial growth factor (VEGF) (Eisermann et al., 1988; Khorram et al., 1993; Keenan et al., 1994; Ryan et al., 1995; Akoum et al., 1996; Arici et al., 1996; Ho et al., 1996; McLaren et al., 1996; Punnonen et al., 1996; Arici et al., 1997; Harada et al., 1997; Gazvani et al., 1998; Zeyneloglu et al., 1998; Mahnke et al., 2000) . All of these cytokines are increased in the peritoneal¯uid (PF) of women with endometriosis. In most cases (RANTES, MCP-1, IL-6, IL-8) levels correlate with the severity of the disease. However, in some cases there is an inverse correlation between cytokine levels and the stage of endometriosis .
Angiogenic factors are involved in the pathogenesis of endometriosis Harada et al., 2001; Arici, 2002) . VEGF, also known as vascular permeability factor, is one of the most potent and speci®c. PF-activated macrophages are a major source of VEGF in endometriosis, and VEGF expression is directly regulated by estradiol and progesterone (McLaren et al., 1996) . IL-8, another potent angiogenic agent, is also postulated to play a role in endometriosis. IL-8 is a chemoattractant for neutrophils, is produced in human endometrial tissues (Arici et al., 1998a) and induces proliferation of endometrial stromal cells thereby acting as an autocrine growth factor (Arici et al., 1998b) .
Leptin, an adipocyte hormone and recently described type-1 cytokine, has angiogenic properties and appears to have a relationship with some reproductive processes (Sierra-Honigmann et al., 1998; Fantuzzi and Faggioni, 2000; Sabogal and Munoz, 2001; Moschos et al., 2002) . Several small studies have already demonstrated elevated leptin in the PF of women with endometriosis. Matarese et al. measured leptin concentrations in 13 women with endometriosis and found higher levels in serum and PF compared with controls (Matarese et al., 2000) . De Placido et al. (2001) studied 18 women with endometriosis and con®rmed elevated PF leptin levels in women with endometriosis, although levels were signi®cantly higher with stage I±II versus III±IV disease. However, in a study of 20 women with endometriosis we were unable to demonstrate signi®cant differences in serum leptin between women with and without endometriosis (Matalliotakis et al., 2000) . Moreover, in that study serum leptin levels actually increased during medical therapy with either danazol or depot leuprolide, and returned to previous levels after cessation of treatment.
These studies, with their limited sample sizes and somewhat contradictory ®ndings motivated us to investigate PF leptin levels in women with and without endometriosis. We also sought to examine the suggested relationships between leptin, the stage of endometriosis and the effects of medical treatment. Finally, we documented variations in PF leptin levels during the menstrual cycle.
Materials and methods
Peritoneal¯uid samples were obtained from 60 women with endometriosis undergoing laparoscopy at Yale±New Haven Hospital for evaluation of infertility or pelvic pain, and from 18 controls undergoing tubal sterilization. The Human Investigation Committee at Yale University approved the study, and informed consent was obtained from each woman prior to surgery. In 10 patients, eight of whom had stage III±IV endometriosis, a GnRH agonist (Depot Lupron; TAP Pharmaceuticals, USA) had been used during the 6 months prior to the surgery. None of these 10 women had undergone pelvic surgery in the 6 months prior to initiating treatment with the GnRH agonist.
Participants with previously untreated endometriosis were classi®ed into three groups according to the operative ®ndings: women with super®cial peritoneal endometriosis (n = 24), women with deep endometriotic implants (n = 18), and women with endometriomas (n = 8). The depth of invasion of peritoneal implants was based on the visual impression of the excised lesion(s) at the time of surgery. All surgeries were performed by reproductive endocrinologists with extensive experience in endometriosis surgery, and a threshold of 5 mm was used to distinguish super®cial from deep. The extent of endometriosis was also scored according to the revised classi®cation of the American Fertility Society (1985) , and biopsy specimens were taken to con®rm the diagnosis histologically. Endometriosis implants included both typical and atypical lesions. All patients underwent laparoscopy under general anaesthesia the morning after fasting for b12 h.
The phase of the menstrual cycle was determined by the patient's last menstrual period and was con®rmed by histological dating of the endometrium in 14/18 controls and 38/50 untreated endometriosis cases. Controls were equally divided between the proliferative and secretory phase of the menstrual cycle. Twenty-one endometriosis cases were in the proliferative phase and 17 in the secretory phase of the menstrual cycle.
The PF was collected by aspiration from the posterior cul-de-sac at the beginning of laparoscopy. Samples were not used if bleeding into the pelvic cavity from the abdominal stab punctures was observed. The PF sample was placed in a sterile tube and centrifuged at 600 g for 10 min. The supernatant was collected and stored at ±80°C until assayed.
Determination of leptin
The leptin levels in the PF of women with and without endometriosis were detected by enzyme-linked immunosorbent assay (ELISA). The inter-and intra-assay coef®cients of variation were <5%. The primary antibody used in this work was purchased from Santa Cruz Biotechnology, Inc. (USA). This af®nity-puri®ed rabbit polyclonal antibody (sc-843; IgG) reacts with leptin of mouse, rat and human origin. The secondary antibody was goat anti-mouse IgG, (Fab¢) 2 fragment speci®c, horse-radish peroxidase-conjugated (Pierce, USA).
The ELISA experiments were performed as follows. Brie¯y, PF samples at a concentration of 1:100 in carbonate buffer pH 9.6 were coated in 96-well¯at bottom plates (Sarstedt, Germany), incubated overnight at 4°C and washed four times in 5% Tween-20 (Sigma, USA). The remaining protein-free sites in the plate were blocked by 2% phosphate-buffered saline±bovine serum albumin (PBS±BSA) solution after an incubation of 2 h at room temperature. After washing four times, 100 ml of primary antibody diluted in 0.1% PBS±BSA were added and incubated for 1 h at room temperature. Extensive washing of the plates was followed by addition of 100 ml of secondary antibodies coupled to horse-radish peroxidase (1:1000 dilution; Sigma) and incubated for 1 h at room temperature, in the dark. Finally, the reaction was developed by adding 100 ml/well of tetramethyl benzidine±H 2 O 2 (Sigma) for 20 min. The enzymatic reaction was stopped with 50 ml H 2 SO 4 (4 N). Optical density was measured at 450 nm using a Titertec ELISA photometer (Digiscan; ASYS Hitech GmbH, Austria). The results are expressed as factor concentrations calculated from the corresponding standard curves.
Statistical analysis
Non-parametric data were described as median and parametric data as mean T SD. An unpaired t-test was used for comparison of means and Mann±Whitney U-test for medians. Differences between groups were analysed using Fisher's exact test for non-parametric data. Correlation analysis was performed by Spearman's rank test. Note that in the correlation analysis, both stage of disease and depth of invasion (super®cial = 1, deep = 2, endometrioma = 3) were treated as ordinal variables. P < 0.05 was accepted as statistically signi®cant.
Results
There was no signi®cant difference in mean age between controls (31.2 T 6.9 years), women with untreated endometriosis (32.5 T 6) and women undergoing GnRH agonist treatment for endometriosis (32.7 T 6). Moreover, no signi®-cant difference was seen in body mass index among the above groups (mean 22.1±22.9 kg/m 2 ).
The mean concentration of PF leptin was signi®cantly higher in women with untreated endometriosis compared with controls (Table I ). This ®nding was consistent throughout the different phases of the menstrual cycle. However, PF leptin levels were signi®cantly higher in the secretory versus the proliferative phase of the menstrual cycle.
In women with endometriosis who were not on GnRH agonist therapy, mean leptin levels were signi®cantly higher with super®cial peritoneal disease (38.2 T 5.1 ng/ml) than with deep peritoneal implants (32.0 T 8.1 ng/ml; P < 0.001) or endometriotic cysts (27.4 T 8.2 ng/ml; P = 0.004). A negative correlation was found between PF leptin levels and the depth of invasion (super®cial, deep, endometrioma) of endometriosis (r = ±0.50, P < 0.001). Similarly, the stage of endometriosis was inversely correlated with PF leptin levels (r = ±0.62, P < 0.001).
Signi®cantly higher concentrations of PF leptin were found in stage I±II (combined mean 38.3 T 6.1 ng/ml) than stages III±IV endometriosis (combined mean 26.3 T 4.8 ng/ml; P < 0.001; Figure 1 ). The discriminating point occurred between stage II and stage III (37.3 T 7.5 versus 26.1 T 3.2 ng/ml; P < 0.001). Nevertheless, even women with stage III±IV endometriosis had signi®cantly higher PF leptin levels than controls (P < 0.01). Women with stage III±IV endometriosis treated with a GnRH agonist (Lupron) prior to surgery (n = 8) demonstrated signi®cantly lower PF leptin levels (20.3 T 4.8 ng/ml) than untreated women with stage III±IV endometriosis. There was no signi®cant difference in PF leptin levels between controls and women treated with a GnRH agonist. Finally, among women with untreated endometriosis, no signi®cant difference in PF leptin levels was found between women with infertility (36 ng/ml) and women with pelvic pain (34.5 ng/ml).
Discussion
We ®nd that leptin is signi®cantly increased in the PF of women with endometriosis. This observation is in accordance with previous smaller studies demonstrating that PF leptin levels were signi®cantly higher in women with endometriosis than controls (Matarese et al., 2000; De Placido et al., 2001) . We have also shown that PF leptin levels are higher in women with super®cial, minimal±mild stage endometriosis than those with more invasive, advanced stage disease. Indeed, we note a signi®cant decline in PF leptin levels with advancing depth of invasion and stage of disease. Again, this con®rms earlier, small studies suggesting that PF leptin may be more elevated in women with early than advanced stage endometriosis (Matarese et al., 2000; De Placido et al., 2001) .
There is evidence that estradiol and progesterone mediate serum leptin levels (Messinis et al., 2001) . A rise in serum leptin has consistently been documented in the luteal and late follicular phase of both natural and gonadotrophin-stimulated cycles (Mannucci et al., 1998; Messinis et al., 1998; Yamada et al., 2000) . Our PF data complement the observation that serum leptin concentrations are higher in the secretory phase than in the proliferative phase of the cycle Messinis et al., 2001) . However, we ®nd that despite variation during the menstrual cycle, PF leptin levels are signi®cantly higher in women with endometriosis than controls in both phases of the cycle.
An interesting ®nding in this study is that women with stage III±IV endometriosis undergoing medical treatment with GnRH agonist had lower PF leptin levels than women with similar stage, previously untreated disease. In fact, PF leptin levels in women on GnRH agonist were similar to controls undergoing spontaneous menstrual cycles. In pre-menopausal women who undergo bilateral oophorectomy a signi®cant drop in serum leptin levels has been documented . Interestingly, this decline may be prevented by the exogenous administration of estradiol plus progesterone (Messinis et al., 2000) . If changes in serum leptin levels closely correlate with changes in PF leptin levels, one might predict a decline in PF leptin after GnRH agonist treatment to levels below those of normally cycling women.
Although we know of no data speci®cally addressing PF leptin levels in post-menopausal women, we found the similarity between controls and women treated with GnRH agonist to be somewhat surprising. One possible explanation is that factors related to the presence of endometriosis sustain leptin production in the absence of estrogen/progesterone. Both the leptin receptor and, to a lesser extent, leptin itself are expressed in human endometrium (Gonzalez et al., 2000; Kitawaki et al., 2000; Gonzalez and Leavis, 2001 ). Moreover, Figure 1 . Peritoneal¯uid (PF) leptin levels in women with endometriosis divided according to the stage of disease. Women with stage I±II endometriosis had signi®cantly (*P < 0.001) higher PF leptin levels than women with stage III±IV endometriosis, women with stage III±IV endometriosis previously treated with Lupron and controls. Additionally, women with stage III±IV had signi®cantly higher PF leptin levels (**P < 0.01) than women with stage III±IV endometriosis previously treated with Lupron or controls. Data are presented as mean T SD. 
Values are expressed in ng/ml as mean T SD (range). a Proliferative versus secretory phase leptin in the control group: P < 0.001. b Proliferative versus secretory phase leptin in women with endometriosis: P < 0.001.
Peritoneal¯uid leptin in endometriosis the expression of leptin mRNA and protein are signi®cantly increased in endometriosis cells compared with eutopic endometrium (Wu et al., 2002) . Finally, although endometriosis cells express the leptin receptor, mRNA levels for the receptor decrease in association with increasing stages of the disease (Wu et al., 2002) . Thus, endometriosis implants are both a potential source of leptin production and a potential target for its action, particularly in stages I±II of the disease. On the basis of these ®ndings, it is tempting to hypothesize that leptin may be an active participant in the pathogenesis of peritoneal endometriosis. Leptin is known to stimulate angiogenesis (Bouloumie et al., 1998; Sierra-Honigmann et al., 1998; Cao et al., 2001; Park et al., 2001) . Angiogenesis is believed to be a necessary requirement for the sustenance of endometriosis implants. Leptin also induces vascular permeability, and synergistically stimulates angiogenesis with VEGF and ®broblast growth factor-2 (Cao et al., 2001) . Moreover, TNF and IL-1 are known to increase leptin production (Janik et al., 1997; Zumbach et al., 1997) .
Leptin has also been shown to induce expression of matrix metalloproteinases both in vivo and in vitro (Park et al., 2001) . Matrix metalloproteinases are believed to play a critical role in the initial invasion of endometrial cells into the mesothelium (Spuijbroek et al., 1992; Arici, 2002) . In addition, high doses of leptin have been shown to signi®cantly enhance mitogenic activity in cultured eutopic and ectopic endometrial stromal cells (Wu et al., 2002) . Thus, leptin may provide a link between acute in¯ammation, angiogenesis, invasion of the mesothelium and endometrial stromal proliferation.
In conclusion, leptin has intrinsic angiogenic and mitogenic properties, may be induced by in¯ammatory cytokines, and induces matrix metalloproteinases. PF leptin levels are elevated in women with endometriosis, particularly in minimal± mild stage, peritoneal disease. Moreover, despite¯uctuations during the menstrual cycle, PF leptin levels remain in both phases signi®cantly higher in women with endometriosis than controls. Finally, prolonged exposure to a GnRH agonist suppresses endometriotic implants and lowers PF leptin to levels comparable with control populations. All of these characteristics strongly suggest a role for leptin in the pathogenesis of stage I±II, peritoneal endometriosis.
